Compare MFA & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | AURA |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.0M | 797.5M |
| IPO Year | 1998 | 2021 |
| Metric | MFA | AURA |
|---|---|---|
| Price | $8.60 | $6.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $11.05 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.4M | 628.3K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.16% | N/A |
| EPS Growth | ★ 58.54 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | $36.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.36 | $4.73 |
| 52 Week High | $10.43 | $9.54 |
| Indicator | MFA | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 29.62 |
| Support Level | N/A | $6.10 |
| Resistance Level | $8.99 | $6.69 |
| Average True Range (ATR) | 0.15 | 0.32 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 30.91 | 8.10 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.